Skip to Content


Medically reviewed by Last updated on Jun 7, 2020.


(FLOO ta mide)

Index Terms

  • Eulexin
  • Flucinom
  • Flugerel
  • Niftolid
  • SCH 13521

Dosage Forms

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Capsule, Oral:

Generic: 125 mg

Pharmacologic Category

  • Antineoplastic Agent, Antiandrogen


Flutamide is a nonsteroidal antiandrogen that inhibits androgen uptake and/or inhibits binding of androgen in target tissues.


Oral: Rapid and complete


Extensively hepatic to ≥6 metabolites, primarily 2-hydroxyflutamide (active)


Primarily urine (as flutamide and metabolites); feces (~4%)

Time to Peak

~2 hours (2-hydroxyflutamide [active metabolite])

Half-Life Elimination

~6 hours (2-hydroxyflutamide [active metabolite])

Protein Binding

Parent drug: 94% to 96%; 2-hydroxyflutamide: 92% to 94%

Special Populations: Renal Function Impairment

The half-life of the active metabolite is slightly prolonged in patients with CrCl <29 mL/minute.

Special Populations: Elderly

The half-life is prolonged to ~9.6 hours (active metabolite at steady state).

Use: Labeled Indications

Prostate cancer (metastatic): Management of locally confined Stage B2 to C and Stage D2 metastatic prostate cancer (in combination with a luteinizing hormone-releasing hormone [LHRH] agonist). For Stage B2 to C prostate cancer, flutamide treatment (and goserelin) should start 8 weeks prior to initiating radiation therapy and continue during radiation therapy. To achieve treatment benefit in Stage D2 metastatic prostate cancer, initiate flutamide with the LHRH agonist and continue until disease progression.

Guideline recommendations: The American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline for systemic therapy in men with metastatic castration-resistant prostate cancer suggests that data regarding the clinical benefit of older antiandrogens (including flutamide) are limited, and that older antiandrogen agents may be less efficacious compared to contemporary antiandrogen agents. However, older antiandrogen agents may be offered in patients with low prostate cancer disease burden or limited therapy options (ASCO [Basch 2014]).


Hypersensitivity to flutamide or any component of the formulation; severe hepatic impairment (evaluate baseline hepatic enzymes prior to treatment).

Dosing: Adult

Prostate cancer, metastatic (alternate agent; in patients with low disease burden): Oral: 250 mg 3 times daily (every 8 hours) in combination with a luteinizing hormone-releasing hormone agonist.

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Geriatric

Refer to adult dosing.


May be administered with or without food. Administer orally in 3 divided doses (every 8 hours).


Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Dispense with a child-resistant closure in a tight, light-resistant container.

Drug Interactions

Choline C 11: Antiandrogens may diminish the therapeutic effect of Choline C 11. Monitor therapy

Dapsone (Topical): May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents. Monitor therapy

Indium 111 Capromab Pendetide: Antiandrogens may diminish the diagnostic effect of Indium 111 Capromab Pendetide. Avoid combination

Local Anesthetics: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Local Anesthetics. Specifically, the risk for methemoglobinemia may be increased. Monitor therapy

Nitric Oxide: May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents. Combinations of these agents may increase the likelihood of significant methemoglobinemia. Monitor therapy

Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia. Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia. Avoid lidocaine/prilocaine in infants receiving such agents. Monitor therapy

Sodium Nitrite: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Sodium Nitrite. Combinations of these agents may increase the likelihood of significant methemoglobinemia. Monitor therapy

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.


Endocrine & metabolic: Hot flash (46% to 61%), galactorrhea (9% to 42%), decreased libido (36%), increased lactate dehydrogenase (transient; mild)

Gastrointestinal: Diarrhea (12% to 40%), vomiting (11% to 12%)

Genitourinary: Impotence (33%), cystitis (16%), breast tenderness

Hematologic & oncologic: Rectal hemorrhage (14%), tumor flare

Hepatic: Increased serum AST (transient; mild)

1% to 10%:

Cardiovascular: Edema (4%), hypertension (1%)

Central nervous system: Anxiety, confusion, depression, dizziness, drowsiness, headache, insomnia, nervousness

Dermatologic: Skin rash (3% to 8%), ecchymoses, pruritus

Endocrine & metabolic: Gynecomastia (9%)

Gastrointestinal: Nausea (9%), proctitis (8%), gastric distress (4% to 6%), anorexia (4%), constipation, dyspepsia, increased appetite

Genitourinary: Hematuria (7%)

Hematologic & oncologic: Anemia (6%), leukopenia (3%), thrombocytopenia (1%)

Infection: Herpes zoster

Neuromuscular & skeletal: Weakness (1%)

<1%, postmarketing, and case reports: Cholestatic jaundice, hemolytic anemia, hepatic encephalopathy, hepatic failure, hepatic necrosis, hepatitis, hypersensitivity pneumonitis, increased blood urea nitrogen, increased gamma-glutamyl transferase, increased serum ALT, increased serum bilirubin, increased serum creatinine, jaundice, macrocytic anemia, malignant neoplasm of breast (male), methemoglobinemia, myocardial infarction, oligospermia, pulmonary embolism, skin photosensitivity, sulfhemoglobinemia, thrombophlebitis, urine discoloration (amber, yellow-green)

ALERT: U.S. Boxed Warning

Hepatic injury:

There have been postmarketing reports of hospitalization and rarely death due to liver failure in patients taking flutamide. Evidence of hepatic injury included elevated serum transaminase levels, jaundice, hepatic encephalopathy and death related to acute hepatic failure. The hepatic injury was reversible after discontinuation of therapy in some patients. Approximately half of the reported cases occurred within the initial 3 months of treatment with flutamide.

Serum transaminase levels should be measured prior to starting treatment with flutamide. Flutamide is not recommended in patients whose ALT values exceed twice the upper limit of normal. Serum transaminase levels should then be measured monthly for the first 4 months of therapy, and periodically thereafter. Liver function tests also should be obtained at the first signs and symptoms suggestive of liver dysfunction (eg, nausea, vomiting, abdominal pain, fatigue, anorexia, “flu-like” symptoms, hyperbilirubinuria, jaundice, right upper quadrant tenderness). If at any time, a patient has jaundice, or their ALT rises above 2 times the upper limit of normal, flutamide should be immediately discontinued with close follow-up of liver function tests until resolution.


Concerns related to adverse effects:

• Aniline toxicity: 4-nitro-3-fluoro-methylaniline is a flutamide metabolite. Patients with G6PD deficiency, hemoglobin M disease, and/or smokers are at risk of toxicities associated with aniline exposure, including methemoglobinemia, hemolytic anemia, and cholestatic jaundice; consider monitoring methemoglobin levels.

• Gynecomastia: Gynecomastia may occur in patients receiving flutamide in combination with medical castration.

• Hepatic failure: [US Boxed Warning]: Postmarketing reports of hospitalization and death (rare) due to liver failure have been reported with flutamide. Evidence of hepatic injury included elevated serum transaminases, jaundice, hepatic encephalopathy, and death related to acute hepatic failure. Hepatotoxicity was reversible after discontinuation in some cases. In about half of reported cases, the onset of hepatotoxicity occurred within the first 3 months of flutamide treatment. Monitor serum transaminase levels at baseline, monthly for 4 months, and periodically thereafter. Obtain LFTs at the first symptoms suggestive of liver dysfunction (nausea, vomiting, abdominal pain, fatigue, anorexia, "flu-like" symptoms, hyperbilirubinuria, jaundice, or right upper quadrant tenderness). Use is not recommended in patients with ALT values >2 times ULN. Discontinue flutamide immediately in patients with jaundice or if ALT rises above 2 times ULN; closely monitor LFTs until resolution. Use is contraindicated in patients with severe hepatic impairment.

Disease-related concerns:

• Cardiovascular disease: Androgen-deprivation therapy may increase the risk for cardiovascular disease (Levine 2010).

Special populations:

• Females: Flutamide is not indicated for use in females and should not be used in females, particularly for nonserious or non-life-threatening conditions.

Monitoring Parameters

Serum transaminases (at baseline, monthly for 4 months, and periodically thereafter); monitor liver function tests at the first sign or symptom of liver dysfunction (eg, nausea, vomiting, abdominal pain, fatigue, anorexia, flu-like symptoms, hyperbilirubinuria, jaundice, or right upper quadrant tenderness); monitor prostate specific antigen (PSA). Consider monitoring methemoglobin levels in patients with hemoglobin M disease or with G6PD deficiency and in smokers. Monitor adherence.

Reproductive Considerations

Although flutamide is not indicated for use in females, it has been used off label for acne, hirsutism, polycystic ovary syndrome (PCOS), and female pattern hair loss in women. Due to the potential for serious toxicity and the availability of other treatment options, off-label use for these conditions is not recommended (Azarchi 2019; ES [Goodman 2015]); ES [Martin 2018]). Effective contraception is recommended if used in females for these conditions (Azarchi 2019).

Women treated with flutamide for PCOS may have a return of regular menses and ovulatory cycles (Paradisi 2013).

Pregnancy Risk Factor


Pregnancy Considerations

Based on the mechanism of action and data from animal reproduction studies, in utero exposure to flutamide may cause fetal harm.

Patient Education

What is this drug used for?

• It is used to treat prostate cancer.

• It may be given to you for other reasons. Talk with the doctor.

All drugs may cause side effects. However, many people have no side effects or only have minor side effects. Call your doctor or get medical help if any of these side effects or any other side effects bother you or do not go away:

• Hot flashes

• Diarrhea, upset stomach, or throwing up

• Enlarged breasts

• Lowered interest in sex

• Not able to get or keep an erection

WARNING/CAUTION: Even though it may be rare, some people may have very bad and sometimes deadly side effects when taking a drug. Tell your doctor or get medical help right away if you have any of the following signs or symptoms that may be related to a very bad side effect:

• Liver problems like dark urine, feeling tired, not hungry, upset stomach or stomach pain, light-colored stools, throwing up, or yellow skin or eyes

• Blood in the urine

• Bleeding from rectum or rectal pain

• Feeling very tired or weak

• Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing, swallowing, or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.

Note: This is not a comprehensive list of all side effects. Talk to your doctor if you have questions.

Consumer Information Use and Disclaimer: This information should not be used to decide whether or not to take this medicine or any other medicine. Only the healthcare provider has the knowledge and training to decide which medicines are right for a specific patient. This information does not endorse any medicine as safe, effective, or approved for treating any patient or health condition. This is only a limited summary of general information about the medicine’s uses from the patient education leaflet and is not intended to be comprehensive. This limited summary does NOT include all information available about the possible uses, directions, warnings, precautions, interactions, adverse effects, or risks that may apply to this medicine. This information is not intended to provide medical advice, diagnosis or treatment and does not replace information you receive from the healthcare provider. For a more detailed summary of information about the risks and benefits of using this medicine, please speak with your healthcare provider and review the entire patient education leaflet.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Frequently Asked Questions